05:25 PM EST, 02/26/2026 (MT Newswires) -- Crinetics Pharmaceuticals ( CRNX ) reported a Q4 loss late Thursday of $1.29 per diluted share, wider than a loss $0.88 a year earlier.
Analysts polled by FactSet expected a loss of $1.35.
Revenue for the quarter ended Dec. 31 was $6.2 million.
Analysts surveyed by FactSet expected $4.5 million.